Drug Trial Radar · NCT02588677
Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)
Last checked: Nov 19, 2026Latest source record: Sep 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
394
Actual
Start
Apr 2013
Primary completion
Dec 5, 2016
Study completion Mar 2018
Sponsor
- Lead sponsor
- AB ScienceIndustry
- Sponsor type
- Industry
- First posted
- Oct 28, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective is to compare the efficacy and safety of masitinib in combination with riluzole in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS).
Conditions
- Amyotrophic Lateral Sclerosis (ALS)
Interventions
Masitinib (4.5)Drug
4.5 mg/kg/day
RiluzoleDrug
PlaceboDrug
Masitinib (3.0)Drug
3 mg/kg/day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Amyotrophic Lateral Sclerosis functional rating scale (ALSFRS)-RevisedTime frame: From baseline to week 48
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital Carlos III
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.